title: Personalized one-two punches for lung cancer.
abstract: Discovery of individualized therapies to address resistance to tyrosine kinase inhibitors (TKIs) has been hampered by the inability to test drug combinations on patient samples before and after TKI resistance. A recent study published in Science by Crystal et al. describes a methodology for pharmacological screening using a panel of 76 targeted agents and cell lines made directly from patient biopsies.
authors.affiliation: 1] Program in Molecular Biology, University of Colorado Cancer Center, Aurora, CO 80045, USA [2] Department of Biochemistry and Molecular Genetics, University of Colorado Cancer Center, Aurora, CO 80045, USA.
authors.forename: Hannah A
authors.initials: HA
authors.lastname: Scarborough
authors.affiliation: Department of Medicine, School of Medicine, University of Colorado Cancer Center, Aurora, CO 80045, USA.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Bunn
authors.affiliation: 1] Program in Molecular Biology, University of Colorado Cancer Center, Aurora, CO 80045, USA [2] Department of Biochemistry and Molecular Genetics, University of Colorado Cancer Center, Aurora, CO 80045, USA [3] Department of Medicine, School of Medicine, University of Colorado Cancer Center, Aurora, CO 80045, USA.
authors.forename: James
authors.initials: J
authors.lastname: DeGregori
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D066230:Patient-Specific Modeling; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors